[A24-108] Epcoritamab (DLBCL, third line) - Benefit assessment according to §35a Social Code Book V
Last updated 17.04.2025
Project no.:
A24-108
Commission:
Commission awarded on 01.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more prior systemic therapies
- Patients who are eligible for CAR-T cell therapy or stem cell therapy: added benefit not proven
- Patients who are not eligible for CAR-T cell therapy and stem cell therapy: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-108
| Project no. | Title | Status |
|---|---|---|
| G23-27 | Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| A24-95 | Epcoritamab (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G25-14 | Epcoritamab (diffuse large B-cell lymphoma [DLBCL]) – Addendum to Project A24-108 | Commission completed |
Federal Joint Committee (G-BA)
17.04.2025 A G-BA decision was published.
G-BA documents on this decision